1Nakashima M Uemura K Kosuge K et al.Phase Ⅰ clinical study of pazufloxacin mesilate [J].Japan J Chemother,1999,47(1):141-141.
2Kobayashi H. Interim results from a multicentre clinical trial of T-3761 in Japan[J].Drug ,1995,49 (Suppl 2): 470-471.
3Muratani T,Inoue M,Mitsuhashi S. In vitro of T-3761,a new fluoroquinolone[J].Antimicrobial Agent and Chemotherapy,1992,36(10):2293-2303.
4Klopman G,Fercu D,Renau TE,et al. N-1-tert-Butyl-Substitued quinolones:in vitro anti-Mycobacterium activities and structure-activity relationship studies[J].Antimicrobial Agent and Chemotherapy,1996,40(11):2637-2643.
5Furuhata K,Hiraiwa T,Ono S,et al. General pharmacology of T-3761,a new oral quinolone antibacterial agent(1).Effect on the central nervous agent[J].Jpn J Antibiot,1995,48(5):692-705.
6Fukuda H,Kawamura Y. Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate,a new quinolone antibacterial agent for intravenous use:convulsions in mice after intravenous or intracerebroventricular administration[J].Jpn J Antibiot,2002,55(3):270-280.
7Furuhata K,Hayakawa H,Soumi K,et al. Histamine-releasing properties of T-3761,a novel fluoroquinolone antimicrobial agent in intravenous use.I.Effect of dose and infusion rate on blood pressure,heart rate and plasma histamine concentration[J].Biol Pharm Bull,1998,21(5):456-460.
8Furuhata K,Fukuda Y,Soumi K,et al. Histamine-releasing properties of T-3762,a novel fluoroquinolone antimicrobial agent in intravenous use II. Dermovascular permeability increasing effect and action on peritoneal mast cells[J].Biol Pharm Bull,1998,21(5):461-464.
9Nakagawa S,Iwai N,Komae N,et al. Single administration toxicity studies of T-3761 in mice,rats and dogs[J].Jpn J Antibiot,1995,48(6):754-768.
10Kawamura Y,Nagai A,Yoshida K,et al. Three months oral repeated dose toxicity of T-3761 in rats[J].Jpn J Antibiot,1995,48(6):769-789.
